About Our Company

AdjuTec Pharma AS is a Norwegian pharmaceutical start-up company that was founded in 2019 based on research in antibiotic products at the University of Oslo (UoO), Norway.

The company management includes five people that together with world-class advisors and a highly competent board has the required in-house expertise to progress our R&D, business development and fund-raising activities.

AdjuTec Pharma's largest shareholder is the founder, Professor Emeritus Pål Rongved at the UoO. Together with experienced investors, the company is well positioned to take our pipeline products to the market.

The company vision is to provide novel antibiotic resistance breakers to meet the imminent threat to modern medicine of antimicrobial resistance (AMR).

AdjuTec Pharma's core technology is the synthesis of β-lactamase inhibitors (BLIs) that inactivates bacteria resistance enzymes. By taking down bacteria defense we are able to preserve susceptibility of broad-spectrum antibiotics.

Supported by private funding and public grants AdjuTec Pharma has completed the initial preclinical development and the First-In-Man study of its lead compound APC148.